Equities

EKF Diagnostics Holdings PLC

EKF:LSE

EKF Diagnostics Holdings PLC

Health CareMedical Equipment and Services
  • Price (GBX)25.00
  • Today's Change0.40 / 1.63%
  • Shares traded40.80k
  • 1 Year change-4.03%
  • Beta0.2404
Data delayed at least 20 minutes, as of Feb 06 2026 16:35 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy1
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast

The 3 analysts offering 12 month price targets for EKF Diagnostics Holdings PLC have a median target of 35.00, with a high estimate of 37.00 and a low estimate of 34.00. The median estimate represents a 40.00% increase from the last price of 25.00.
High48.0%37.00
Med40.0%35.00
Low36.0%34.00

Earnings history & estimates

EKF Diagnostics Holdings PLC reported annual 2024 earnings of 1.45 per share on Mar 25, 2025.
Average growth rate-13.49%
More ▼

Revenue history & estimates

EKF Diagnostics Holdings plc had revenues for the full year 2024 of 50.19m. This was 4.59% below the prior year's results.
Average growth rate-4.70%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.